Prognostic value of FDG-PET in patients with ovarian carcinoma following surgical treatment

Annals of Nuclear Medicine

Volumn 20, Issue 3, 2006, Pages 171-174

  Kurosaki, Hiromasa ^a,b   Oriuchi, Noboru ^c   Okazaki, Atsushi ^a   Tamaki, Tomoaki ^a   Uki, Akiyoshi ^a   Izuta, Masato ^a   Kojima, Rieko ^a   Kato, Yoshio ^a   Higuchi, Tetsuya ^c   Maruno, Hirotaka ^a  

^a TORANOMON HOSPITAL   (Japan)

^b Funabashi Municipal Medical Center   (Japan)

^c GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CA 125; FDG PET; Ovarian carcinoma; Survival

Indexed keywords

CA 125 ANTIGEN; FLUORODEOXYGLUCOSE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG UPTAKE; FEMALE; FOLLOW UP; HUMAN; OVARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME;

FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INCIDENCE; JAPAN; LONGITUDINAL STUDIES; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33745282686     PISSN: 09147187     EISSN: 09147187     Source Type: Journal    
DOI: 10.1007/BF03027426     Document Type: Article

References (13)

1. 18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 2000; 10: 761-767.
2. 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Anticancer Res 2001; 21: 3691-3694.
3. Nakamoto Y, Saga T, Ishimori T, Mamede M, Togashi K, Higuchi T, et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR Am J Roentgenol 2001; 176: 1449-1454.
4. Torizuka T, Nobezawa S, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose. Eur J Nucl Med Mol Imaging 2002; 29: 797-803.
5. Zimny M, Siggelkow W, Schroder W, Nowak B, Biemann S, Rath W, et al. 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 2001; 83: 310-315.
6. 18F] FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma. Eur J Nucl Med Mol Imaging 2004; 31: 196-201.
7. Rustin G, Tuxen M. Use of CA-125 in follow-up of ovarian cancer. Lancet 1996; 20; 348: 191-192.
8. Zanaboni F, Presti M, Scarfone G, Bolis G. CA-125 reliability in predicting ovarian cancer recurrence. Tumori 1989; 75: 69-71.
9. Gronlund B, Hogdall C, Hilden J, Engelholm SA, Hogdall EV, Hansen HH. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol 2004; 22: 4051-4058.
10. Makar AP, Kristensen GB, Bormer OP, Trope CG. Is serum CA-125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer? Gynecol Oncol 1993; 49: 3-7.
11. Gadducci A, Landoni F, Maggino T, Sartori E, Zola P, Ferdeghini M, et al. Serum CA-125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study. Int J Gynecol Cancer 1997; 7: 78-83.
12. Khan N, Oriuchi N, Yoshizaki A, Kanuma T, Higuchi T, Endo K. Diagnostic accuracy of FDG PET imaging for the detection of recurrent or metastatic gynecologic cancer. Ann Nucl Med 2005; 19: 137-145.
13. Hogberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol 2001; 40: 340-360.